Fingolimod for the treatment of relapsing multiple sclerosis

Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of lymphocytes in lymphoid tissue. Effector memory T cells are not sequestered so that immune surveillance may be minimally affected. Two large-scale Phase III clinical trials have demonstrated the efficacy of fingolimod compared with placebo and intramuscular interferon β-1a in relapsing–remitting multiple sclerosis. Due to its mechanism of action, fingolimod administration may be associated with first-dose bradycardia and macular edema. Therefore, patients should be observed for 6 h at the time of their first dose and undergo ophthalmologic evaluation prior to treatment initiation and at 3–4 months after initiation.

[1]  M. Keezer,et al.  Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. , 2010, Clinical immunology.

[2]  G. Ingram,et al.  WHAT IS THE RISK OF PERMANENT DISABILITY FROM A MULTIPLE SCLEROSIS RELAPSE? , 2010, Neurology.

[3]  L. Kappos,et al.  Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis , 2010, Neurology.

[4]  M. Laouri,et al.  Burden of illness of diabetic macular edema: literature review , 2010, Current medical research and opinion.

[5]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[6]  L. Wilkins.  Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study , 2010, Neurology.

[7]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[8]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[9]  H. Hartung,et al.  Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis , 2010, Clinical neuropharmacology.

[10]  X. Montalban,et al.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results , 2010, Multiple sclerosis.

[11]  J. Wolinsky,et al.  Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1352458509358088 , 2022 .

[12]  Arthur L. Allen,et al.  Factors that influence adherence with disease-modifying therapy in MS , 2009, Journal of Neurology.

[13]  X. Montalban,et al.  Oral fingolimod (FTY720) in multiple sclerosis , 2009, Neurology.

[14]  E. Gulbins,et al.  Sphingolipids in the lungs. , 2008, American journal of respiratory and critical care medicine.

[15]  D S Goodin,et al.  Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review) , 2008, Neurology.

[16]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[17]  B. Trapp,et al.  Multiple sclerosis: an immune or neurodegenerative disorder? , 2008, Annual review of neuroscience.

[18]  B Stubinski,et al.  Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results , 2009, Multiple sclerosis.

[19]  J. Antel,et al.  FTY720 modulates human oligodendrocyte progenitor process extension and survival , 2008, Annals of neurology.

[20]  H. J. Kim,et al.  Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells , 2007, Glia.

[21]  J. Cyster,et al.  Finding a way out: lymphocyte egress from lymphoid organs , 2007, Nature Immunology.

[22]  S. Sorbi,et al.  Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis , 2007, European Neurology.

[23]  E. Persohn,et al.  Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.

[24]  S. Payne,et al.  The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[25]  C. A. Foster,et al.  FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis , 2007, Brain Research Bulletin.

[26]  Nathalie Arbour,et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.

[27]  L. Durelli,et al.  Adherence to interferon-beta treatment and results of therapy switching , 2007, Journal of the Neurological Sciences.

[28]  M. Schwab,et al.  Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors , 2007, Journal of neurochemistry.

[29]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[30]  L. Obeid,et al.  Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  K. Dev,et al.  Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors , 2007, Neuropharmacology.

[32]  T. Ohmori,et al.  Essential Roles of Sphingosine 1‐Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury , 2007, Stem cells.

[33]  M. Salvadori,et al.  Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation , 2006, Transplantation.

[34]  V. Brinkmann,et al.  FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. , 2006, International immunopharmacology.

[35]  M. Salvadori,et al.  FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  Y. Bae,et al.  Sphingosylphosphorylcholine stimulates human monocyte-derived dendritic cell chemotaxis , 2006, Acta Pharmacologica Sinica.

[37]  L. Kappos,et al.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.

[38]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[39]  N. Rouach,et al.  S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK , 2006, The European journal of neuroscience.

[40]  R. Proia,et al.  Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.

[41]  S. Spiegel,et al.  Novel role of sphingosine kinase 1 as a mediator of neurotrophin‐3 action in oligodendrocyte progenitors , 2005, Journal of neurochemistry.

[42]  T. Hla,et al.  Structural and functional characteristics of S1P receptors , 2004, Journal of cellular biochemistry.

[43]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  R. Rudick,et al.  Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS , 2004 .

[45]  J. Chun,et al.  Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.

[46]  J. Chun,et al.  Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes , 2004, International Journal of Developmental Neuroscience.

[47]  V. Peponis,et al.  Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. , 2004, Ophthalmology.

[48]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[49]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.

[50]  R. Proia,et al.  G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. , 2003, Blood.

[51]  J. Chun,et al.  Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes , 2003, Brain Research.

[52]  S. Milstien,et al.  Pleiotropic actions of sphingosine-1-phosphate. , 2003, Progress in lipid research.

[53]  T. Hla.  Signaling and biological actions of sphingosine 1-phosphate. , 2003, Pharmacological research.

[54]  Y. Yamori,et al.  Sphingosine 1‐phosphate induces the production of glial cell line‐derived neurotrophic factor and cellular proliferation in astrocytes , 2003, Glia.

[55]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[56]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[57]  T. Chin,et al.  Distinct effects of different calcium-mobilizing agents on cell death in NG108-15 neuroblastoma X glioma cells. , 2002, Molecular pharmacology.

[58]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.

[59]  S. Kikuchi,et al.  Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons , 1999, Brain Research.

[60]  Y. Yanagawa,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L‐positive T cells in Peyer’s patches by FTY720‐induced lymphocyte homing , 1998, Immunology.

[61]  S. Spiegel,et al.  Sphingosine‐1‐Phosphate in Cell Growth and Cell Death a , 1998, Annals of the New York Academy of Sciences.

[62]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[63]  C. H. Liu,et al.  Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. , 1998, Science.

[64]  S. Spiegel,et al.  Involvement of Sphingosine 1-Phosphate in Nerve Growth Factor-Mediated Neuronal Survival and Differentiation , 1997, The Journal of Neuroscience.

[65]  P. Calabresi,et al.  Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure , 1997, Neurology.

[66]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[67]  S. Milstien,et al.  Sphingolipid metabolites: Members of a new class of lipid second messengers , 1995, The Journal of Membrane Biology.

[68]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[69]  R. Pabst,et al.  Distribution of lymphocyte subsets and natural killer cells in the human body , 1992, The clinical investigator.

[70]  S. Reingold,et al.  Revised estimate of the prevalence of multiple sclerosis in the united states , 1992, Annals of neurology.

[71]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[72]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[73]  L. Kappos,et al.  Oral fingolimod (FTY720) treatment reduces peripheralIL-17-producing TH17 cells in patients with multiple sclerosis , 2008 .

[74]  A. Verma.  The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .

[75]  Uhc Campus.  Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study , 2005 .

[76]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[77]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[78]  Lewis R. Lipsey,et al.  The Merck Manual of Diagnosis and Therapy , 1988, The Yale Journal of Biology and Medicine.

[79]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.